Contribution of immunohistochemistry in the differential diagnosis of non-small cell lung carcinomas on small biopsy samples.

摘要: Summary Purpose: Targeted therapy increases survival and the quality of life non-small cell lung cancer (NSCLC) patients but it needs precise histological subtyping. The present study evaluated 6 monoclonal antibodies for differential diagnosis NSCLC on small-sized tissue samples. Methods: 50 samples were obtained by bronchoscopy or fine needle aspiration biopsy (FNAB). According to morphology before immunohistochemistry 2 squamous carcinomas (SCC), adenocarcinomas (AC), 9 NSCLC-probably SCC, 11 AC 22 unclassified NSCLCs diagnosed. Thyroid transcription factor-1 (TTF-1), cytokeratin 5/6, 7, p63, neuroendocrine markers CD56 synaptophysin used in NSCLC. Results: After 13 (26.0%) 27 (54.0%) AC, 3 (6.0%) with differentiation (NSCLC-NE) 7 (14.0%) NSCLC- Twenty-two further diagnosed as SCC (n=7), (n=7) NSCLC-NE (n=2) remained unclassified. Significant difference was found between definitely 8 15 ACs (20.5 vs. 38.5%, p=0.008). TTF-1 expressed 85.2% (23/27) 5/6 p63 100% (13/13) SCC. Positivity determined NSCLC-NE. Conclusion: No one antibody is totally specified type tumor its origin. Combination TTF-1, allows Napsin-A chromogranin A should be added an optimal panel.